Filing Flows › Bio-Rad Laboratories (BIO) › Q3 2026 › vs Q3 2025
Bio-Rad Laboratories (BIO) Q3 2026 vs Q3 2025 (year over year)
Bio-Rad Laboratories's revenue rose $3.4M (+0.5%) from $653M in Q3 2025 to $656M in Q3 2026. The biggest changes: Clinical Diagnostics +$10.6M (+3%); Life Science −$7.2M (-3%).
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.9% | 13.7% | -3.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Clinical Diagnostics | $402M | $391M | $10.6M | +3% |
| Life Science | $255M | $262M | −$7.2M | -3% |
| Revenue | $656M | $653M | $3.4M | +0.5% |
| Other income, net | $588M | −$496M | $1.1B | — |
| Costs & expenses | $1.2B | $1.1B | $161M | +15% |
| Operating costs | $706M | $588M | $118M | +20% |
| Income tax | $80.1M | −$89.2M | $169M | — |
| Net earnings | $459M | −$342M | $800M | — |
| Cost of revenue | $328M | $310M | $18.2M | +6% |
| Research & development | $71.4M | $71.3M | $100K | +0.1% |
| SG&A | $257M | $207M | $50.3M | +24% |
| Operating cash sources | $474M | −$327M | $801M | — |
| Share-based compensation | $15.5M | $14.9M | $600K | +4% |
| Working capital & other | $378M | −$448M | $826M | — |
| Operating cash flow | $96.4M | $121M | −$24.5M | -20% |
| Free cash flow (OCF − capex) | $65.2M | $89.2M | −$24.0M | -27% |
| Capital expenditures | $31.2M | $31.7M | −$500K | -2% |
Questions
How much did Bio-Rad Laboratories's revenue grow year over year in Q3 2026?
Bio-Rad Laboratories's revenue rose $3.4M (+0.5%) from $653M in Q3 2025 to $656M in Q3 2026.
What drove Bio-Rad Laboratories's revenue change in Q3 2026?
Clinical Diagnostics +$10.6M (+3%); Life Science −$7.2M (-3%).